DARA Biosciences Inc  

(Public, NASDAQ:DARA)   Watch this stock  
Find more results for David Clements
-0.030 (-3.34%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.86 - 0.90
52 week 0.79 - 4.40
Open 0.90
Vol / Avg. 120,129.00/338,217.00
Mkt cap 17.55M
P/E     -
Div/yield     -
EPS -1.51
Shares 19.50M
Beta 1.50
Inst. own 10%
Sep 12, 2014
DARA Biosciences Inc at Aegis Capital Corp Healthcare & Technology Conference
Sep 9, 2014
DARA Biosciences Inc at Rodman & Renshaw Global Investment Conference
Aug 13, 2014
Q2 2014 DARA Biosciences Inc Earnings Call - Webcast
Aug 12, 2014
Q2 2014 DARA Biosciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -644.95% -2472.53%
Operating margin -640.76% -2501.51%
EBITD margin - -2351.12%
Return on average assets -66.66% -105.36%
Return on average equity -73.06% -122.67%
Employees 13 -
CDP Score - -


Suite 160, 8601 Six Forks Road
United States - Map
+1-816-9147027 (Phone)
+1-919-8610239 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


DARA BioSciences, Inc. is a specialty pharmaceutical company primarily focused on the commercialization of oncology treatment and oncology supportive care pharmaceutical products. The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy (CCIPN). Its primary focus is on the commercialization of the oncology treatment and oncology supportive care pharmaceutical products, which include Soltamox, Cancer support therapeutics and Three Mission Pharmacal products. The Company�s oral liquid products can provide a alternative to solid dose formulations for those patients with dysphagia, or difficulty swallowing, or those who simply prefer to take drug products in liquid form.

Officers and directors

David J. Drutz M.D. Executive Chairman of the Board, Chief Medical Officer
Age: 76
Bio & Compensation  - Reuters
Christopher G. Clement President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Haywood D. Cochrane Jr. Independent Vice Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
David L. Tousley Acting Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Timothy J. Heady Independent Director
Age: 59
Bio & Compensation  - Reuters
Gail F. Lieberman Independent Director
Age: 70
Bio & Compensation  - Reuters
Paul J. Richardson Independent Director
Age: 57
Bio & Compensation  - Reuters